NCT03215277 - A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

May 25, 2020

Study Completion Date

May 25, 2020

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Bimekizumab

One bimekizumab dose will be administered.

DRUG

Certolizumab pegol

Two certolizumab pegol doses will be administered. One of these doses is a loading dose.

OTHER

Placebo

Placebo will be provided to maintain the blinding.

Trial Locations (34)

32174

As0013 908, Ormond Beach

38119

As0013 906, Memphis

68516

As0013 903, Lincoln

73103

As0013 902, Oklahoma City

Unknown

As0013 202, Kladno

As0013 205, Ostrava

As0013 201, Prague

As0013 203, Prague

As0013 302, Berlin

As0013 306, Berlin

As0013 304, Erlangen

As0013 303, Hamburg

As0013 301, Herne

As0013 405, Athens

As0013 404, Heraklion

As0013 401, Pátrai

As0013 402, Thessaloniki

As0013 406, Thessaloniki

As0013 501, Chisinau

As0013 601, Amsterdam

As0013 708, Bialystok

As0013 709, Krakow

As0013 706, Olsztyn

As0013 703, Poznan

As0013 702, Torun

As0013 701, Warsaw

As0013 704, Warsaw

As0013 707, Wroclaw

As0013 801, Kazan'

As0013 803, Kemerovo

As0013 806, Moscow

As0013 807, Moscow

As0013 802, Yaroslavl

As0013 805, Yaroslavl

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY